are met." However, Novo Nordisk owns multiple patents protecting its medications that use semaglutide, including the diabetes drug Ozempic, and said that organizations selling semaglutide products "may be infringing Novo Nordisk's intellectual property rights and/or violating applicable law." The company added that it "will take such actions as it deems necessary and appropriate to protect its intellectual property rights." "Nobody knows how [compounding pharmacies are] getting it," said Karl Nadolsky, an endocrinologist at Spectrum Health
GLP-1 is a hormone released in the gut after meals, signaling fullness, slowing gastric emptying, and helping control blood sugar levels
short sequential cohort about -4.7% during the initial 2.5 mg phase and -12.7% by the end of the 5 mg phase (Barrea EXCLI Journal 2026)
Moreover, for general glycemic control, GLP-1 RAs are now often preferred over insulin when injectable therapy is needed, unless there is severe uncontrolled hyperglycemia
No participant withdrew from any trial due to treatment-related adverse effects
On top of that, serve yourself half your normal portion size and wait 15-20 minutes before you decide if you want more